Re-transplantation after bortezomib-based therapy

British Journal of Haematology

Volumn 153, Issue 5, 2011, Pages 666-668

  Morris, Curly ^a   Cook, Gordon ^b   Streetly, Matthew ^c   Kettle, Paul ^a   Drake, Mary ^a   Quinn, Michael ^a   Cavet, Jim ^d   Tighe, Jane ^e   Kazmi, Majit ^c   Ashcroft, John ^f   Cook, Mark ^g   Snowden, John ^h   Olujohungbe, Ade ⁱ   Marshall, Scott ^j   Conn, Jane ^k   Oakervee, Heather ^l   Popat, Rakesh ^l   Cavenagh, Jamie ^l  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^j CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

^k NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^l BARTS HEALTH NHS TRUST   (United Kingdom)

more..

Author keywords

Bortezomib; Myeloma; Second autologous transplantation

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; INTERFERON; MELPHALAN; METHYLPREDNISOLONE; THALIDOMIDE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETRANSPLANTATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 79955731774     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08521.x     Document Type: Letter

References (9)

1. Bensinger, W. (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. Journal of Clinical Oncology, 26, 480-492.
2. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
3. Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
4. Laubach, J.P., Mahindra, A., Mitsiades, C.S., Schlossman, R.L., Munshi, N.C., Ghobrial, I.M., Carreau, N., Hideshima, T., Anderson, K.C. & Richardson, P.G.. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia, 23, 2222-2232.
5. Lonial, S. & Cavenagh, J. (2009) Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology, 145, 681-708.
6. Oakervee, H.E., Popat, R., Curry, N., Smith, P., Morris, C., Drake, M., Agrawal, S., Stec, J., Schenkein, D., Esseltine, D.L. & Cavenagh, J.D. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology, 129, 755-762.
7. Olin, R.L., Vogl, D.T., Porter, D.L., Luger, S.M., Schuster, S.J., Tsai, D.E., Siegel, D.L., Cook, R.J., Mangan, P.A., Cunningham, K. & Stadtmauer, E.A. (2009) Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplantation, 43, 417-422.
8. Rajkumar, S.V., Fonseca, R., Lacy, M.Q., Witzig, T.E., Lust, J.A., Greipp, P.R., Therneau, T.M., Kyle, R.A., Litzow, M.R. & Gertz, M.A. (1999) Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplantation, 23, 1267-1272.
9. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.